DSM announces biologics agreement with Paranta Biosciences
DSM will manufacture recombinant human protein at Brisbane, Australia plant
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has signed a biologics contract manufacturing agreement with Paranta Biosciences of Melbourne, Australia. Financial terms were not disclosed.
Under the contract DSM will carry out the process development and cGMP manufacture of Paranta‘s leading recombinant human protein. This project represents an agreement for DSM with an Australian customer at its Brisbane facility.
Paranta Biosciences is an early stage drug development company dedicated to developing and commercialising novel biotherapeutics based on recombinant human follistatin for the treatment of respiratory diseases.
Alexander Wessels, CEO of DSM Pharmaceutical Products, said: ‘Working with Paranta is an important milestone for DSM to support the local client base directly from our facility in Australia, expanding our presence in global regions.’
Ross Barrow, CEO of Paranta Biosciences, said: ‘Follistatin has been shown to have great potential in treating a wide range of inflammatory and fibrotic respiratory diseases, which affect more than 300 million people worldwide. Our selection of DSM as Paranta‘s biologics manufacturing partner is the culmination of an extensive global search process spanning more than nine months.
‘We are looking forward to working with the Groningen and Brisbane groups of DSM Biologics as we continue the development and manufacturing scale-up of what we believe will be a truly exciting biotherapeutic.’
In addition to an R&D and manufacturing site in Groningen, The Netherlands, DSM is building operations in Brisbane, Australia, with the support of the Governments of Queensland and the Commonwealth. The Brisbane facility is DSM's blueprint for its ‘biologics plant of the future‘ for the production of biopharmaceuticals.